- Home
- EFR vs CDXC Comparison
EFR vs CDXC Comparison
Compare EFR & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFR
- CDXC
- Stock Information
- Founded
- EFR 2003
- CDXC 1999
- Country
- EFR United States
- CDXC United States
- Employees
- EFR N/A
- CDXC N/A
- Industry
- EFR Trusts Except Educational Religious and Charitable
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- EFR Finance
- CDXC Health Care
- Exchange
- EFR Nasdaq
- CDXC Nasdaq
- Market Cap
- EFR 382.5M
- CDXC 415.5M
- IPO Year
- EFR N/A
- CDXC N/A
- Fundamental
- Price
- EFR $13.09
- CDXC $6.09
- Analyst Decision
- EFR
- CDXC Strong Buy
- Analyst Count
- EFR 0
- CDXC 2
- Target Price
- EFR N/A
- CDXC $8.00
- AVG Volume (30 Days)
- EFR 88.6K
- CDXC 431.2K
- Earning Date
- EFR 01-01-0001
- CDXC 03-05-2025
- Dividend Yield
- EFR 9.43%
- CDXC N/A
- EPS Growth
- EFR N/A
- CDXC N/A
- EPS
- EFR 1.69
- CDXC 0.02
- Revenue
- EFR N/A
- CDXC $91,668,000.00
- Revenue This Year
- EFR N/A
- CDXC $18.64
- Revenue Next Year
- EFR N/A
- CDXC $20.72
- P/E Ratio
- EFR $7.74
- CDXC $311.55
- Revenue Growth
- EFR N/A
- CDXC 9.95
- 52 Week Low
- EFR $10.95
- CDXC $1.36
- 52 Week High
- EFR $13.29
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- EFR 59.38
- CDXC 57.85
- Support Level
- EFR $12.87
- CDXC $5.17
- Resistance Level
- EFR $13.09
- CDXC $5.52
- Average True Range (ATR)
- EFR 0.15
- CDXC 0.26
- MACD
- EFR 0.01
- CDXC 0.10
- Stochastic Oscillator
- EFR 89.71
- CDXC 86.92
About EFR Eaton Vance Senior Floating-Rate Fund of Beneficial Interest
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of health care, industrial equipment, lodging and casinos, oil and gas, publishing, radio and television, telecommunications, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.